Summary
Recently, we cloned from platelet mRNA a novel cyclooxygenase (COX)-2 splice variant,
designated COX-2a, which is characterized by a partial deletion of exon 5. Preliminary
studies of mRNA distribution of COX-2 isoforms in platelets from coronary artery bypass
grafting (CABG) patients showed a variable increase in COX-2a mRNA expression after
cardiac surgery. Thus, we assessed whether this variant may play a functional role
in these patients. We report a marked (about 20346-fold) increase in the expression
of COX-2a mRNA after CABG. Evidence is presented that ribosomal frame-shifting may
correct the coding sequence resulting in the expression of a full-length COX-2a pro-tein.
In addition, a reading frame-corrected COX-2a mutant (COX-2aΔG) was generated by site-directed
mutagenesis and expressed in COS-7 cells using an adenoviral expression system. However,
COX-2a protein was not active in terms of prostaglandin formation. Thus, alternative
mRNA splicing might represent an intriguing posttranscriptional mechanism to oppose
a transcriptional activation of the COX-2 gene. Evolutionary, this mechanism may prevent
COX-2-dependent thromboxane synthesis in the platelet, which would potentiate the
likelihood of thrombosis; pharmacologically, this mechanism would prevent an aspirin-insensitive
pathway of thromboxane formation.
Keywords
Platelet COX-2 - COX-2a - aspirin - thromboxane - CABG - qPCR